Sorin gets Committee for Proprietary Medicinal Products (CPMP) approval for TecneMAB:
This article was originally published in Clinica
Executive Summary
Sorin Biomedica's malignant melanoma imaging agent TecneMAB has been approved by the European Committee for Proprietary Medicinal Products. Although the decision was made on May 23rd it normally takes about two months for companies to receive written permission to begin marketing controlled products. Sorin, which is based in Saluggia, Italy, developed the technetium-99-labelled antibody in the mid-1980s.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.